Megan Hollasch

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication OncologyLive, aiding in all aspects of the publication process, as well as content for OncLive.com.

Articles

Hematologic Oncology Field Sees Almost 20 FDA Approvals in 2024

February 11th 2025

The movement of CAR T-cell therapy to earlier lines of therapy was among many notable advancements greenlit by the FDA in the hematologic space in 2024.

Alisertib Plus Ibrutinib and Rituximab Shows Preclinical Efficacy in MCL Models

February 10th 2025

Alisertib plus ibrutinib and rituximab showed anti-tumor activity in mantle cell lymphoma in a preclinical study.

Bladder Cancer Care Shifts as BCG Shortage Lingers, With Investigative Combinations and Tools at the Forefront

February 10th 2025

Vikram M. Narayan, MD, details updates in the bladder cancer field, including effects of the BCG shortage and upcoming therapies/tools of interest.

Experts Comment on the GI/GU Cancer FDA Approvals From 2024

February 10th 2025

Experts provide insights on the 2024 FDA approvals in the gastrointestinal and genitourinary fields in this list featuring all the regulatory decisions.

Advanced Breast Cancer at Diagnosis Linked to 10% Higher CVD Risk

February 7th 2025

Kevin T. Nead, MD, MPhil, details findings on the association between prevalent CVD and breast cancer and next steps for investigating the connection.

Eribulin Proves Noninferior to Taxane as Combination Partner With Trastuzumab and Pertuzumab in HER2+ Breast Cancer

February 6th 2025

Adding eribulin to trastuzumab/pertuzumab rather than taxane resulted in a numerically longer median time to QOL deterioration and similar efficacy outcomes in HER2+ breast cancer.

Beyond TKIs: Synthetic Lethal Approaches and Targeted Therapies to Watch in Lung Cancer

February 5th 2025

Leveraging synthetic lethal approaches in lung cancer with new targets and agents may be a promising avenue of investigation.

Secondary Primary Cancer Prevention Strategies Following CAR T-Cell Therapy Are Underway

February 4th 2025

Optimized T-cell manufacturing is one strategy that may prevent SPCs after CAR T-cell therapy, according to Shyam A. Patel, MD, PhD, and Saurabh Dahiya, MD, FACP.

A Road Map for Change Report Provides a Guide to Elevate Breast Cancer Care

February 3rd 2025

Coauthor of the Lancet Breast Cancer Commission report, Reshma Jagsi, MD, DPhil, details the 6 themes of the evidence-based plan aimed to address challenges in the field.

CAR T-Cell Therapy Results in Secondary Primary Cancers in Approximately 4% of Patients

January 31st 2025

Shyam A. Patel, MD, PhD, and Saurabh Dahiya, MD, FACP, detail the pathobiology of SPCs after CAR T-cell therapy and findings from a review on the cancers.

Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer

January 30th 2025

The addition of chemotherapy to radiation therapy following surgery conferred a benefit in certain endometrial cancer molecular subtypes.

The ADC OQY-3258 Demonstrates Early Efficacy in Multiple Breast Cancer Subtypes

January 30th 2025

OQY-3258 (ESG401) showed preliminary efficacy in multiple breast cancer subtypes, including TNBC and HR+/HER2- breast cancer.

MB-105 Receives Orphan Drug Designation in Relapsed/Refractory CD5+ T-Cell Lymphoma

January 30th 2025

The FDA has granted orphan drug designation to the CAR T-cell therapy MB-105 in CD5-positive T-cell lymphoma.

Second Primary Cancer Risk Informs the Risk-Benefit Profile of CAR T-Cell Therapies

January 29th 2025

CAR T-cell therapies are associated with a risk for second primary cancers, and mitigation strategies for these toxic effects are warranted and under examination.

Tissue-Based NGS May Help Determine Relevant Gene Copy Number Gain Cutpoint for HER2/KRAS/MET in NSCLC

January 29th 2025

Findings from an oncogene overlap study in NSCLC support the potential clinical impact of high-level amplification of MET, HER2, and KRAS defined by NGS.

Watson Unpacks the Potential Clinical Impact of High-Level MET, HER2, and KRAS Amplifications in NSCLC

January 28th 2025

Alexander Watson, MD, DPhil, FRCPC, explains how the relationship between driver positivity and amplification status affects same-gene alteration enrichment.

Cabozantinib Bests Placebo in Extrapancreatic NETs With Primary Tumor Arising in the Gl Tract

January 24th 2025

A subgroup analysis of the CABINET trial showed that cabozantinib extended PFS vs placebo in extrapancreatic NETs with a primary tumor arising in the GI tract.

Driver-Positive Tumor Frequency Decreases With Increasing Copy Number Gain in NSCLC

January 23rd 2025

Alexander Watson, MD, DPhil, FRCPC, details findings showing oncogene overlap is adequately applied to NGS-based tissue sampling by decreasing frequency and increasing copy number gain.

Second Cycle of Medicare Drug Price Negotiations Includes 4 Oncologic Agents

January 22nd 2025

The CMS has selected 15 drugs covered under Medicare Part D for the second cycle of the Drug Price Negotiation Program, including enzalutamide, pomalidomide, palbociclib, and acalabrutinib.

Precision Medicine Heats Up Ahead of SOGO Annual Meeting in GI Cancer

January 21st 2025

E. Gabriela Chiorean, MD, FASCO, discusses exciting targeted therapies in the GI space and topics to be discussed at the School of Gastrointestinal Oncology meeting.